Evidence map›Paper›PMID 25662495›Full record

ArticleBiomaterials2015

Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction.

Sonya B Sonnenberg, Aboli A Rane, Cassie J Liu, Nikhil Rao, Gillie Agmon, Sophia Suarez, Raymond Wang, Adam Munoz, Vaibhav Bajaj, Shirley Zhang and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 99 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. New treatment methods for myocardial infarction.Frontiers in cardiovascular medicine · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. CD73Frontiers in cell and developmental biology · 2021
    Article
  16. Growth factor-eluting hydrogels for management of corneal defects.Materials science & engineering. C, Materials for biological applications · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Sonya B SonnenbergDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Aboli A RaneDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Cassie J LiuDepartment of Chemical Engineering, The Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Department of Bioengineering, The Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Nikhil RaoDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Gillie AgmonDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Sophia SuarezDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Raymond WangDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Adam MunozDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Vaibhav BajajDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Shirley ZhangDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Rebecca BradenDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Pamela J Schup-MagoffinDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
Oi Ling KwanDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Anthony N DeMariaDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jennifer R CochranDepartment of Chemical Engineering, The Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Department of Bioengineering, The Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Karen L ChristmanDepartment of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA. Electronic address: christman@eng.ucsd.edu.
University of California, San Diego · USSanford Consortium for Regenerative Medicine · USStanford University · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
San Diego Clinical and Translational Research InstituteUL1TR000100 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2015
$19.7M
Extracellular matrix hydrogels for treating ischemiaR01HL113468 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHRISTMAN, KAREN L · 2012 to 2020
$3.1M
Engineered HGF-NK1 antagonists for Met-targeted cancer imaging and therapyR01CA151706 · NCI · STANFORD UNIVERSITY · PI COCHRAN, JENNIFER R · 2010 to 2014
$1.6M
NCATS NIH HHS 5UL1TR000100NCATS NIH HHS UL1 TR000100NCATS NIH HHS UL1 TR001442NCI NIH HHS R01 CA151706NCI NIH HHS R01CA151706NHLBI NIH HHS R01 HL113468NHLBI NIH HHS R01HL113468
6 · The paper itself

Abstract

Hepatocyte growth factor (HGF) has been shown to have anti-fibrotic, pro-angiogenic, and cardioprotective effects; however, it is highly unstable and expensive to manufacture, hindering its clinical translation. Recently, a HGF fragment (HGF-f), an alternative c-MET agonist, was engineered to possess increased stability and recombinant expression yields. In this study, we assessed the potential of HGF-f, delivered in an extracellular matrix (ECM)-derived hydrogel, as a potential treatment for myocardial infarction (MI). HGF-f protected cardiomyocytes from serum-starvation and induced down-regulation of fibrotic markers in whole cardiac cell isolate compared to the untreated control. The ECM hydrogel prolonged release of HGF-f compared to collagen gels, and in vivo delivery of HGF-f from ECM hydrogels mitigated negative left ventricular (LV) remodeling, improved fractional area change (FAC), and increased arteriole density in a rat myocardial infarction model. These results indicate that HGF-f may be a viable alternative to using recombinant HGF, and that an ECM hydrogel can be employed to increase growth factor retention and efficacy.

Indexed as

Drug Delivery SystemsProtein EngineeringVentricular RemodelingAnimalsBlood VesselsCell SizeDisease Models, AnimalExtracellular MatrixFemaleFibrosisHeart Function TestsHepatocyte Growth FactorHumansHydrogel, Polyethylene Glycol DimethacrylateMyocardial InfarctionMyocytes, CardiacHepatocyte Growth FactorHydrogel, Polyethylene Glycol DimethacrylatePeptide FragmentsProto-Oncogene Proteins c-metDecellularizationExtracellular matrixGrowth factorHydrogelMyocardial infarction

Identifiers

PMID25662495
PMCPMC4326250
OpenAlexW1978788204

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.